These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 24929162)

  • 21. Rectal radiation dose-reduction techniques in prostate cancer: a focus on the rectal spacer.
    Leiker AJ; Desai NB; Folkert MR
    Future Oncol; 2018 Nov; 14(26):2773-2788. PubMed ID: 29939069
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Proposed rectal dose constraints for patients undergoing definitive whole pelvic radiotherapy for clinically localized prostate cancer.
    Chan LW; Xia P; Gottschalk AR; Akazawa M; Scala M; Pickett B; Hsu IC; Speight J; Roach M
    Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):69-77. PubMed ID: 18342454
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dosimetric impact and theoretical clinical benefits of fiducial markers for dose escalated prostate cancer radiation treatment.
    Gauthier I; Carrier JF; Béliveau-Nadeau D; Fortin B; Taussky D
    Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1128-33. PubMed ID: 19147306
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact on rectal dose from the use of a prostate immobilization and rectal localization device for patients receiving dose escalated 3D conformal radiation therapy.
    Sanghani MV; Ching J; Schultz D; Cormack R; Loffredo M; McMahon E; Beard C; D'Amico AV
    Urol Oncol; 2004; 22(3):165-8. PubMed ID: 15271308
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dose-Escalated Stereotactic Body Radiation Therapy for Patients With Intermediate- and High-Risk Prostate Cancer: Initial Dosimetry Analysis and Patient Outcomes.
    Kotecha R; Djemil T; Tendulkar RD; Reddy CA; Thousand RA; Vassil A; Stovsky M; Berglund RK; Klein EA; Stephans KL
    Int J Radiat Oncol Biol Phys; 2016 Jul; 95(3):960-964. PubMed ID: 27302511
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 4π noncoplanar stereotactic body radiation therapy for head-and-neck cancer: potential to improve tumor control and late toxicity.
    Rwigema JC; Nguyen D; Heron DE; Chen AM; Lee P; Wang PC; Vargo JA; Low DA; Huq MS; Tenn S; Steinberg ML; Kupelian P; Sheng K
    Int J Radiat Oncol Biol Phys; 2015 Feb; 91(2):401-9. PubMed ID: 25482301
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sensitivity of treatment plan optimisation for prostate cancer using the equivalent uniform dose (EUD) with respect to the rectal wall volume parameter.
    Schwarz M; Lebesque JV; Mijnheer BJ; Damen EM
    Radiother Oncol; 2004 Nov; 73(2):209-18. PubMed ID: 15542168
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A novel model to correlate hydrogel spacer placement, perirectal space creation, and rectum dosimetry in prostate stereotactic body radiotherapy.
    Hwang ME; Black PJ; Elliston CD; Wolthuis BA; Smith DR; Wu CC; Wenske S; Deutsch I
    Radiat Oncol; 2018 Oct; 13(1):192. PubMed ID: 30285812
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hypofractionated boost to the dominant tumor region with intensity modulated stereotactic radiotherapy for prostate cancer: a sequential dose escalation pilot study.
    Miralbell R; Mollà M; Rouzaud M; Hidalgo A; Toscas JI; Lozano J; Sanz S; Ares C; Jorcano S; Linero D; Escudé L
    Int J Radiat Oncol Biol Phys; 2010 Sep; 78(1):50-7. PubMed ID: 19910135
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rectal endoscopy findings following stereotactic body radiation therapy for clinically localized prostate cancer.
    Sood S; Ju AW; Wang H; Lei S; Uhm S; Zhang G; Suy S; Carroll J; Lynch J; Dritschilo A; Collins SP
    Radiat Oncol; 2013 Aug; 8():197. PubMed ID: 23937800
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-dose-rate brachytherapy as a monotherapy for favorable-risk prostate cancer: a Phase II trial.
    Barkati M; Williams SG; Foroudi F; Tai KH; Chander S; van Dyk S; See A; Duchesne GM
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1889-96. PubMed ID: 21550182
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Toxicity after three-dimensional radiotherapy for prostate cancer with RTOG 9406 dose level IV.
    Michalski JM; Winter K; Purdy JA; Perez CA; Ryu JK; Parliament MB; Valicenti RK; Roach M; Sandler HM; Markoe AM; Cox JD
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):735-42. PubMed ID: 14967428
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Image-guided intensity-modulated radiotherapy for prostate cancer: Dose constraints for the anterior rectal wall to minimize rectal toxicity.
    Peterson JL; Buskirk SJ; Heckman MG; Diehl NN; Bernard JR; Tzou KS; Casale HE; Bellefontaine LP; Serago C; Kim S; Vallow LA; Daugherty LC; Ko SJ
    Med Dosim; 2014; 39(1):12-7. PubMed ID: 24099966
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Polyethylene glycol hydrogel rectal spacer implantation in patients with prostate cancer undergoing combination high-dose-rate brachytherapy and external beam radiotherapy.
    Yeh J; Lehrich B; Tran C; Mesa A; Baghdassarian R; Yoshida J; Torrey R; Gazzaniga M; Weinberg A; Chalfin S; Ravera J; Tokita K
    Brachytherapy; 2016; 15(3):283-287. PubMed ID: 26853354
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dosimetric predictors of radiation-induced lung injury in stereotactic body radiation therapy.
    Ricardi U; Filippi AR; Guarneri A; Giglioli FR; Mantovani C; Fiandra C; Anglesio S; Ragona R
    Acta Oncol; 2009; 48(4):571-7. PubMed ID: 19031164
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low rectal toxicity after dose escalated IMRT treatment of prostate cancer using an absorbable hydrogel for increasing and maintaining space between the rectum and prostate: results of a multi-institutional phase II trial.
    Uhl M; van Triest B; Eble MJ; Weber DC; Herfarth K; De Weese TL
    Radiother Oncol; 2013 Feb; 106(2):215-9. PubMed ID: 23333011
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dose-volume impact in high-dose-rate Iridium-192 brachytherapy as a boost to external beam radiotherapy for localized prostate cancer--a phase II study.
    Pinkawa M; Fischedick K; Treusacher P; Asadpour B; Gagel B; Piroth MD; Borchers H; Jakse G; Eble MJ
    Radiother Oncol; 2006 Jan; 78(1):41-6. PubMed ID: 16271785
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An Investigation of Dosimetric Correlates of Acute Toxicity in Prostate Stereotactic Body Radiotherapy: Dose to Urinary Trigone is Associated with Acute Urinary Toxicity.
    Henderson DR; Murray JR; Gulliford SL; Tree AC; Harrington KJ; Van As NJ
    Clin Oncol (R Coll Radiol); 2018 Sep; 30(9):539-547. PubMed ID: 29807801
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of mean rectal dose on late rectal bleeding after conformal radiotherapy for prostate cancer: dose-volume effect.
    Zapatero A; García-Vicente F; Modolell I; Alcántara P; Floriano A; Cruz-Conde A; Torres JJ; Pérez-Torrubia A
    Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1343-51. PubMed ID: 15275719
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.